Clinical outcomes and patient satisfaction rates among elderly male aged ≥75 years with inflatable penile prosthesis implant for medically refractory erectile dysfunction.

PubWeight™: 1.47‹?› | Rank: Top 5%

🔗 View Article (PMID 23708698)

Published in World J Urol on May 26, 2013

Authors

Eric Chung1, Matt Solomon, Ling DeYoung, Gerald B Brock

Author Affiliations

1: Division of Urology, St Joseph's Health Care, London, ON, Canada, ericchg@hotmail.com.

Articles cited by this

A study of sexuality and health among older adults in the United States. N Engl J Med (2007) 9.66

Changes in sexual function in middle-aged and older men: longitudinal data from the Massachusetts Male Aging Study. J Am Geriatr Soc (2004) 1.64

EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology (1999) 1.52

The natural progression and regression of erectile dysfunction: follow-up results from the MMAS and MALES studies. J Sex Med (2011) 1.52

Should being aged over 70 years hinder penile prosthesis implantation? BJU Int (2009) 1.39

A survey of patients with inflatable penile prostheses: assessment of timing and frequency of intercourse and analysis of implant durability. J Sex Med (2012) 1.38

Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med (2007) 1.37

Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med (2009) 1.28

Historical review of penile prosthesis design and surgical techniques: part 1 of a three-part review series on penile prosthetic surgery. J Sex Med (2009) 1.09

Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med (2010) 1.08

Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol (2001) 1.06

Sex after seventy: a pilot study of sexual function in older persons. J Sex Med (2007) 1.02

Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med (2006) 0.98

A survey of patients with inflatable penile prostheses for satisfaction. J Urol (2005) 0.90

Effects of age, comorbidity and lifestyle factors on erectile function: Tampere Ageing Male Urological Study (TAMUS). Eur Urol (2004) 0.81

Penile prosthesis implantation: size matters. Eur Urol (2006) 0.80

Outcomes of and satisfaction with the inflatable penile prosthesis in the elderly male. Adv Urol (2012) 0.75

Articles by these authors

Fractured penis: diagnosis and management. J Sex Med (2009) 2.68

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology (2010) 2.19

Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia – integrated data from 1,499 study participants. BJU Int (2015) 2.06

Combined transurethral and laparoscopic partial cystectomy and robot-assisted bladder repair for the treatment of bladder endometrioma. J Minim Invasive Gynecol (2006) 1.92

Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol (2004) 1.76

Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol (2004) 1.25

Delayed penile rehabilitation post radical prostatectomy. J Sex Med (2010) 1.09

Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl (2004) 1.09

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int (2011) 1.07

Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie's disease. J Sex Med (2007) 0.96

A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome. J Urol (2012) 0.96

Cryptorchidism and its impact on male fertility: a state of art review of current literature. Can Urol Assoc J (2011) 0.95

Minimizing morbidity in the treatment of penile melanoma: Mohs micrographic surgery and sentinel lymph node biopsy. Can J Urol (2007) 0.92

The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med (2011) 0.91

Penile Doppler sonographic and clinical characteristics in Peyronie's disease and/or erectile dysfunction: an analysis of 1500 men with male sexual dysfunction. BJU Int (2012) 0.90

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol (2007) 0.88

Penile duplex ultrasonography in men with Peyronie's disease: is it veno-occlusive dysfunction or poor cavernosal arterial inflow that contributes to erectile dysfunction? J Sex Med (2011) 0.87

Ca2+-activated Cl- channels in corpus cavernosum smooth muscle: a novel mechanism for control of penile erection. J Appl Physiol (1985) (2002) 0.87

Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol (2004) 0.86

Daily use of sildenafil improves endothelial function in men with type 2 diabetes. J Androl (2011) 0.85

Investigative models in erectile dysfunction: a state-of-the-art review of current animal models. J Sex Med (2011) 0.85

Clinical outcomes of intracavernosal injection in postprostatectomy patients: a single-center experience. Urology (2011) 0.84

Protein biomarker analysis of primary Peyronie's disease cells. J Sex Med (2009) 0.84

Regulation of intracellular Ca2+ release in corpus cavernosum smooth muscle: synergism between nitric oxide and cGMP. Am J Physiol Cell Physiol (2004) 0.84

Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can J Urol (2006) 0.83

Comparison between AMS 700™ CX and Coloplast™ Titan inflatable penile prosthesis for Peyronie's disease treatment and remodeling: clinical outcomes and patient satisfaction. J Sex Med (2012) 0.83

Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique. Urology (2006) 0.82

Erectile dysfunction: monitoring response to treatment in clinical practice--recommendations of an international study panel. J Sex Med (2007) 0.82

Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med (2005) 0.82

Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol (2008) 0.81

Three-year outcomes of recovery of erectile function after open radical prostatectomy with sural nerve grafting. J Sex Med (2014) 0.79

Through the eyes of women: the partners' perspective on tadalafil. Urology (2006) 0.78

Peyronie's disease: evolving surgical management and the role of phosphodiesterase 5 inhibitors. ScientificWorldJournal (2009) 0.78

Surgery: centers of excellence for penile prosthesis: yes or no? Nat Rev Urol (2009) 0.78

Sexual dysfunction in 2011: advances in epidemiology, pathophysiology and treatment. Nat Rev Urol (2012) 0.77

Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl (2012) 0.77

Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction. Curr Urol Rep (2011) 0.77

How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. J Sex Med (2012) 0.77

Intracavernous pharmacotherapy for erectile dysfunction. Endocrine (2004) 0.77

Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions. Can J Plast Surg (2010) 0.76

Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep (2003) 0.76

Peyronie's disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie's disease in a cell-culture strain system. J Sex Med (2013) 0.76

Editorial comment on: Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol (2009) 0.75

Post-pyeloplasty flank pain treated with laparoscopically-assisted renal autotransplantation. Can J Urol (2004) 0.75

Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health. J Am Acad Nurse Pract (2011) 0.75

Daily dosing of PDE5 inhibitors: where does it fit in? Curr Urol Rep (2013) 0.75